BACKGROUND Statins can regress coronary atheroma and lower clinical events. Although pre-clinical studies suggest
S
tatins are the cornerstone for treating atherosclerotic cardiovascular disease and can regress atherosclerosis (1, 2) and lower cardiovascular event rates (3) .
The most recent U.S. guidelines now advocate high-intensity statin therapy (HIST) in all individuals with known atherosclerosis, regardless of baseline lipoprotein levels (4).
Coronary arterial calcification has been extensively evaluated, and the baseline extent of coronary calcium measured noninvasively strongly associates with incident cardiovascular events (5). Underlying this imaging approach is the presumption that coronary calcium scoring using computed tomography (CT) represents a reliable surrogate measure of coronary atheroma volume. Given the direct relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels, serial measures of plaque burden, and cardiovascular events, it is therefore logical to deduce that the effects on both plaque and its calcific component following statin therapy might be concordant. However, prior serial CT evaluations of the effect of statins on coronary calcification yielded conflicting results (6) (7) (8) (9) (10) (11) .
Mechanistic studies have demonstrated the potential procalcific effects of statins in vitro (12) . Coronary intravascular ultrasound (IVUS) has high imaging resolution for measuring atheroma volume, and techniques to measure plaque calcification on IVUS are well described (13) . Moreover, serial coronary IVUS has been pivotal in elucidating factors promoting the progression and regression of coronary atheroma (14) . Using serial coronary IVUS in patients with coronary artery disease, we tested the hypothesis that statin therapy would associate with concordant changes of both coronary atheroma volume and plaque calcification. We specifically compared these changes in patients receiving HIST, low-intensity statin therapy (LIST), and no-statin therapy. From each of these trials, patients receiving HIST (n ¼ 1,545), LIST (n ¼ 1,726), or no-statin therapy (n ¼ 224) were included in the present analysis. In the present analysis, HIST was defined as atorvastatin 80 mg or rosuvastatin 40 mg, whereas LIST was defined as atorvastatin dosing <40 mg, rosuvastatin <20 mg, simvastatin <40 mg, pravastatin <80 mg, lovastatin <20 mg, and fluvastatin dosing <40 mg. Hence, the present analysis comprises a patient-level analysis of 8 randomized trials in which patients were stratified on the basis of statin treatment (or no-statin treatment).
ACQUISITION AND ANALYSIS OF SERIAL IVUS IMAGES.
The acquisition and serial analysis of IVUS images in each of these trials has been previously described in detail (1, 2, 15, (17) (18) (19) (20) (21) (22) . Briefly, target vessels for imaging were selected if they contained no luminal stenosis 
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A P R I L 7 , 2 0 1 5 : 1 2 7 3 -8 2 edges of the lumen and external elastic membrane were traced by manual planimetry. Plaque area was defined as the area occupied between these leading edges. The accuracy and reproducibility of this method have been reported previously (23) . The percent atheroma volume (PAV) was determined by calculating the proportion of the entire vessel wall occupied by atherosclerotic plaque, throughout the segment of interest as follows:
The total atheroma volume (TAV) was calculated by summating the plaque areas in all measured images. To account for heterogeneity of segment length in individual subjects, the TAV was normalized by multiplying the mean atheroma area in each pullback by the median segment length for the entire study cohort as follows: Table 3 describes baseline and changes in PAV and TAV of each treatment group, and pairwise comparisons for changes in atheroma volume following propensity-weighting.
Baseline PAV was 36.9 AE 8.9%, 38.0 AE 9.0%, and 37.2 AE 9.0% in the HIST, LIST, and no-statin groups, respectively. The HIST group had significantly lower Baseline values are mean AE SD, change values are least squares mean AE SE controlling for the baseline counterpart. Pairwise comparisons for baseline IVUS were conducted using the general linear model. Pairwise comparisons for changes in IVUS parameters from baseline were conducted using survey-design inverse probability of treatment weight weighted generalized linear models. *From Wilcoxon signed rank test.
CI ¼ confidence interval; IVUS ¼ intravascular ultrasound. 
DISCUSSION
In this post-hoc propensity-weighted analysis of patients with coronary artery disease undergoing serial In individuals with diabetes, statin use independently Baseline and change in CaI were rank transformed. Average follow-up CRP and triglycerides values were log transformed. *Pearson correlation coefficient (R) between average follow-up lipid parameters and the residuals of change in calcium index using rank analysis of variance, controlling for baseline CaI, baseline plaque burden, change in plaque burden, and clinical trial. †Plaque variable that was adjusted in the model was PAV. ‡Plaque variable that was adjusted in the model was TAV.
Abbreviations as in Tables 2 and 4 . Puri et al.
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